How do monoamine disruptions, glutamatergic dysfunction, and neuroinflammation interact to produce depression in AD?

OPEN

Multiple pathological processes are identified as contributing to depression in AD, but their relative contributions and potential synergistic interactions remain unexplained. This mechanistic understanding is essential for prioritizing therapeutic targets. Gap type: unexplained_observation Source paper: Pathogenesis of Depression in Alzheimer's Disease. (2024, Neurochemical research, PMID:38015411)

Priority: 0.76 Domain: synaptic-biology Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: How do monoamine disruptions, glutamatergic dysfunction, and neuroinflammation interact to produce depression in AD? is a 0.76 priority gap in synaptic-biology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How do monoamine disruptions, glutamatergic dysfunction, and neuroinflammation interact to produce depression in AD? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (21)

entities-rosADentities-histone-methylationADentities-atp7b-geneADTAUADTDP-43AD
▸ Show 16 more

biomarker for (1)

tau cleavage productsAD

causes (6)

ADneurodegenerationPHOSPHORYLATED_TAUADBETA_AMYLOIDADADIMMUNE_TOLADmemory_loss
▸ Show 1 more

contributes to (1)

NEUROINFLAMMATIONAD

cross disease mechanism in (5)

MAPTADTREM2ADNLRP3ADPINK1ADGRNAD

depleted in (1)

SPM_levelsAD

prevents (1)

NAD+ augmentationAD

protective against (1)

cognitive stimulationAD

regulates (1)

ADPROTEOME

risk factor for (4)

genetically at-risk individualsADAPOE ε4ADmicroglial primingADAPOE4AD

targets (1)

resveratrolAD

therapeutic target for (6)

TREM2ADCCR2ADSaracatinibADanti-amyloid antibodiesADNAD+ augmentationAD
▸ Show 1 more

treats (1)

HTL9936AD
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps